Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a patent in Israel for a proprietary combination of opioids and N-acylethanolamines, aimed at enhancing opioid efficacy while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening NeuroThera's global intellectual property protection [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance the analgesic effects of opioids like oxycodone, allowing for effective pain relief at lower doses [3][5]. - Pre-clinical studies demonstrated that the combination of oxycodone and PEA not only improved pain relief but also reduced adverse psychoactive effects associated with oxycodone [5]. Group 2: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant demand for opioid medications [6]. - The opioid-sparing effect of NeuroThera's combination may lead to lower required dosages of opioids, potentially mitigating risks such as addiction and respiratory depression [7]. Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its subsidiary NeuroThera Labs Inc., which is engaged in creating novel therapeutics for central nervous system disorders [9][10]. - The company is also involved in developing cannabinoid-based pharmaceuticals, with ongoing programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [9].

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].